Skip to content

Comparison of marginal bone loss in platform switched and normal abutments with periimplant crevicular fluid biomarkers

Effects of Platform Switched Abutments in Periimplant Crevicular Bone Biomarkers A Randomized One Year Clinical Prospective Study of Platform Switched Abutments in Periimplant Crevicular Bone Biomarkers One Year Clinical Prospective Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210721008
Enrollment
30
Registered
2021-07-21
Start date
2014-04-07
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preventive or screening interventions biomarkers peri-implant bone resorption osteoclastogenesis

Interventions

dental implant application using traditional abutments to the posterior site, marginal bone level,dental implant application using platform switch abutments to the posterior site
Active Comparator Device,Active Comparator Device

Sponsors

Istanbul University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Healty patients in need of at least two implants in the posterior region, sites without acute infection or bone defects, at least 7 mm width of available crestal bone for 3.8 or 4.3 mm implants at least 9 mm height of bone.

Exclusion criteria

Exclusion criteria: Patients with systemic medical conditions, such as diabetes, and/or taking any medication(s) that could influence soft and hard tissue healing mechanisms.

Design outcomes

Primary

MeasureTime frame
Bone loss 12 months Dental radiography,Biomarker analysis 1 and 12 months ELISA

Secondary

MeasureTime frame
Gender distribution 12 months Data analysis

Countries

Turkey

Contacts

Public ContactNecla Kocak Oztug

Istanbul University

asli.kocak@istanbul.edu.tr00905333932245

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026